Takeda Pharmaceutical Co. Ltd. Highlights Data From Clinical Trial of Investigational Norovirus Vaccine Candidate

SAN FRANCISCO & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Takeda) announced today results of a Phase 1/2 study of its intramuscular bivalent (GI/GII) norovirus vaccine candidate in healthy adult volunteers who were challenged with the most commonly occurring norovirus (genotype GII.4) that causes gastroenteritis. The study demonstrated that two doses of the experimental bivalent norovirus were well tolerated, and that the candidate vaccine had a clinically relevant impact on the incidence of norovirus illness after challenge, as well as the severity in breakthrough cases. In addition to the impact on clinical illness, a positive trend toward reduction in viral shedding in stool was observed. The study also provided important information toward optimization of confirmatory lab testing for norovirus disease and infection in a future field trial. The data from that study were highlighted today at an IDWeek 2013-sponsored press conference in San Francisco and will be presented tomorrow as a late-breaking oral presentation at the conference.

Help employers find you! Check out all the jobs and post your resume.